The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Open accessAbstract
Engineering the antibody Fc region to enhance the cytotoxic activity of therapeutic antibodies is currently an active area of investigation. The contribution of complement to the mechanism of action of some antibodies that target cancers and pathogens makes a compelling case for its optimization. Here we describe the generation of a series of Fc variants with enhanced ability to recruit complement. Variants enhanced the cytotoxic potency of an anti-CD20 antibody up to 23-fold against tumor cells in CDC assays, and demonstrated a correlated increase in C1q binding affinity. Complement-enhancing substitutions combined additively, and in one case synergistically, with substitutions previously engineered for improved binding to Fc gamma receptors. The engineered combinations provided a range of effector function activities, including simultaneously enhanced CDC, ADCC, and phagocytosis. Variants were also effective at boosting the effector function of antibodies targeting the antigens CD40 and CD19, in the former case enhancing CDC over 600-fold, and in the latter case imparting complement-mediated activity onto an IgG1 antibody that was otherwise incapable of it. This work expands the toolkit of modifications for generating monoclonal antibodies with improved therapeutic potential and enables the exploration of optimized synergy between Fc gamma receptors and complement pathways for the destruction of tumors and infectious pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
Complement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
Durocher, Y. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.e9 · Cited by 1,037
Engineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803
Self-citationThe 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex
Sondermann, P., Huber, R., Oosthuizen, V., & Jacob, U. (2000) · Nature · doi:10.1038/35018508 · Cited by 719
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Complement: a unique innate immune sensor for danger signals
GASQUE, P. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.06.011 · Cited by 552
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
Vetvicka, V, Thornton, B. P., & Ross, G. D. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118777 · Cited by 407
Gaboriaud, C., Juanhuix, J., Gruez, A., Lacroix, M., Darnault, C., Pignol, D., Verger, D., Fontecilla-Camps, J. C., & Arlaud, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307764200 · Cited by 362
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313
Self-citationEngineered Antibodies with Increased Activity to Recruit Complement
Idusogie, E. E., Wong, P. Y., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Ultsch, M., & Mulkerrin, M. G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2571 · Cited by 291
Shushakova, N., Skokowa, J., Schulman, J., Baumann, U., Zwirner, J., Schmidt, R. E., & Gessner, J. E. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16577 · Cited by 284
Dangl, J. L., Wensel, T. G., Morrison, S. L., Stryer, L., Herzenberg, L. A., & Oi, V. T. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03037.x · Cited by 282
Horton, H. M., Bernett, M. J., Pong, E., Peipp, M., Karki, S., Chu, S. Y., Richards, J. O., Vostiar, I., Joyce, P. F., Repp, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2268 · Cited by 272
Self-citationComplement function in mAb-mediated cancer immunotherapy
Gelderman, K. A., Tomlinson, S., Ross, G. D., & Gorter, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.01.008 · Cited by 262
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Bowles, J. A., Wang, S.-Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M.-A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-020057 · Cited by 227
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Hamaguchi, Y., Uchida, J., Cain, D. W., Venturi, G. M., Poe, J. C., Haas, K. M., & Tedder, T. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4389 · Cited by 212
Treon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Wang, S.-Y., Racila, E., Taylor, R. P., & Weiner, G. J. (2008) · Blood · doi:10.1182/blood-2007-02-074716 · Cited by 194
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Bannerji, R., Kitada, S., Flinn, I. W., Pearson, M., Young, D., Reed, J. C., & Byrd, J. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.012 · Cited by 178
Zhou, X., Hu, W., & Qin, X. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0089 · Cited by 178
Dechant, M., Weisner, W., Berger, S., Peipp, M., Beyer, T., Schneider-Merck, T., Lammerts van Bueren, J. J., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6226 · Cited by 166
The C1q receptor site on immunoglobulin G
Burton, D. R., Boyd, J., Brampton, A. D., Easterbrook-Smith, S. B., Emanuel, E. J., Novotny, J., Rademacher, T. W., van Schravendijk, M. R., Sternberg, M. J. E., & Dwek, R. A. (1980) · Nature · doi:10.1038/288338a0 · Cited by 159
Chu, S. Y., Voštiar, I., Karki, S., Moore, G. L., Lazar, G. A., Pong, E., Joyce, P. F., Szymkowski, D. E., & Desjarlais, J. R. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.06.027 · Cited by 157
Self-citationSpiridon, C., Ghetie, M.-A., Uhr, J. W., Marcheş, R., Li, J. L., Shen, G. L., & Vitetta, E. S. (2002) · PubMed · Cited by 157
Yan, J., Větvička, V., Xia, Y., Coxon, A., Carroll, M. C., Mayadas, T. N., & Ross, G. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.6.3045 · Cited by 149
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
Bowles, J. A., & Weiner, G. J. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.06.018 · Cited by 148
Han, Y., Kozel, T. R., Zhang, M. X., MacGill, R. S., Carroll, M. C., & Cutler, J. E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1550 · Cited by 144
Wang, S., Veeramani, S., Racila, E. V., Cagley, J. R., Fritzinger, D. C., Vogel, C.-W., John, W. S., & Weiner, G. J. (2009) · Blood · doi:10.1182/blood-2009-01-200469 · Cited by 143
Yan, J., Větvička, V., Xia, Y., et al. (1999) · PubMed · Cited by 140
Modulation of the Effector Functions of a Human IgG1 through Engineering of Its Hinge Region
Dall’Acqua, W. F., Cook, K. E., Damschroder, M. M., Woods, R. M., & Wu, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1129 · Cited by 138
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective
Desjarlais, J. R., Lazar, G. A., Zhukovsky, E. A., & Chu, S. Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.009 · Cited by 137
Self-citationComplement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer
Imai, M., Landen, C., Ohta, R., Cheung, N. V., & Tomlinson, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1894 · Cited by 132
Golay, J., Cittera, E., Gaetano, N. D., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L., & Introna, M. (2006) · PubMed · Cited by 129
Kelly‐Quintos, C., Cavacini, L. A., Posner, M. R., Goldmann, D. A., & Pier, G. B. (2006) · Infection and Immunity · doi:10.1128/iai.74.5.2742-2750.2006 · Cited by 121
C5a Initiates the Inflammatory Cascade in Immune Complex Peritonitis
Godau, J., Heller, T., Hawlisch, H., Trappe, M., Howells, E., Best, J. L., Zwirner, J., Verbeek, J. S., Hogarth, P. M., Gerard, C. J., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3437 · Cited by 121
A molecular immunology approach to antibody humanization and functional optimization
Lazar, G. A., Desjarlais, J. R., Jacinto, J. M., Karki, S., & Hammond, P. W. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.029 · Cited by 107
Self-citationMejías, A., Chávez‐Bueno, S., Ríos, A. M., Fonseca-Aten, M., Raynor, B., Peromingo, E., Soni, P., Olsen, K. D., Kiener, P. A., Gomez-Lahoz, A. M., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4700-4707.2005 · Cited by 107
Zent, C. S., Secreto, C. R., LaPlant, B. R., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.05.014 · Cited by 98
Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis
Vugmeyster, Y., Beyer, J. C., Howell, K., Combs, D., Fielder, P. J., Yang, J., Qureshi, F., Sandlund, B., Kawaguchi, L., Dummer, W., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155050.03916.04 · Cited by 79
Kojouharova, M. S., Gadjeva, M. G., Tsacheva, I., Zlatarova, A. S., Roumenina, L. T., Tchorbadjieva, M. I., Atanasov, B. P., Waters, P. J., Urban, B. C., Sim, R. B., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4351 · Cited by 78
Větvička, V., Thornton, B. P., Wieman, T. J., & Ross, G. D. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.2.599 · Cited by 73
Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation
Thommesen, J. E., Michaelsen, T. E., Løset, G. Å., Sandlie, I., & Brekke, O. H. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(01)00010-4 · Cited by 71
Xu, Y., Oomen, R. P., & Klein, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41886-2 · Cited by 69
Structural Difference in the Complement Activation Site of Human IgG1 and IgG3
Michaelsen, T. E., Sandlie, I., Bratlie, D. B., Sandin, R., & Ihle, Ø. (2009) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2009.02338.x · Cited by 50
Paulie, S., Koho, H., Ben-Aissa, H., Hansson, Y., Lundblad, M., & Perlmann, P. (1984) · Cancer Immunology Immunotherapy · doi:10.1007/bf00205482 · Cited by 45
Natsume, A., Shimizu‐Yokoyama, Y., Satoh, M., Shitara, K., & Niwa, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01327.x · Cited by 40
Sensel, M. G., Kane, L. M., & Morrison, S. L. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00112-0 · Cited by 34
Cited by
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Antibody Structure and Function: The Basis for Engineering Therapeutics
Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 638
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Metadata
- Authors
- Moore, G. L., Chen, H., Karki, S., & Lazar, G. A.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 2
- Issue
- 2
- Pages
- 181-189
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W1984342356
- Cited by
- 266
- References
- 57
- FWCI
- 13.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.